Molecular targets to treat muscular dystrophies.

Kinter J, Sinnreich M. Swiss Med Wkly. 2014 Feb 19.

24 febbraio 2014

Injection of a Soluble Fragment of Neural Agrin (NT-1654) Considerably Improves the Muscle Pathology Caused by the Disassembly of the Neuromuscular Junction.

Hettwer S, Lin S, Kucsera S, Haubitz M, Oliveri F, Fariello RG, Ruegg MA, Vrijbloed JW. PLoS One. 2014 Feb 10;9(2)

24 febbraio 2014

The transcriptional coactivator PGC-1α is dispensable for chronic overload-induced skeletal muscle hypertrophy and metabolic remodeling.

Pérez-Schindler J, Summermatter S, Santos G, Zorzato F, Handschin C. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20314-9.

20 dicembre 2013

MAR-mediated integration of plasmid vectors for in vivo gene transfer and regulation.

Puttini S, van Zwieten RW, Saugy D, Lekka M, Hogger F, Ley D, Kulik AJ, Mermod N. BMC Mol Biol. 2013 Dec 2;14:26.

10 dicembre 2013

Functional crosstalk of PGC-1 coactivators and inflammation in skeletal muscle pathophysiology.

Eisele PS, Handschin C. Semin Immunopathol. 2013 Nov 21.

01 dicembre 2013

Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival.

Saxena S, Roselli F, Singh K, Leptien K, Julien JP, Gros-Louis F, Caroni P. Neuron. 2013 Oct 2;80(1):80-96.

15 ottobre 2013

Pharmacological prospects in the treatment of Duchenne muscular dystrophy.

Ruegg UT. Curr Opin Neurol. 2013 Oct;26(5):577-84.

01 ottobre 2013

MTORC1 determines autophagy through ULK1 regulation in skeletal muscle.

Castets P, Rüegg MA. Autophagy. 2013 Sep;9(9):1435-7.

01 settembre 2013

Inhibition of iPLA2 β and of stretch-activated channels by doxorubicin alters dystrophic muscle function.

Ismail HM, Dorchies OM, Perozzo R, Strosova MK, Scapozza L, Ruegg UT. Br J Pharmacol. 2013 Aug;169(7):1537-50

21 agosto 2013

Epidermal growth factor receptor down-regulation triggers human myoblast differentiation.

Leroy MC, Perroud J, Darbellay B, Bernheim L, Konig S. PLoS One. 2013 Aug 15;8(8):e71770

01 agosto 2013